Literature DB >> 21703185

Altered composition of fatty acids exacerbates hepatotumorigenesis during activation of the phosphatidylinositol 3-kinase pathway.

Yotaro Kudo1, Yasuo Tanaka, Keisuke Tateishi, Keisuke Yamamoto, Shinzo Yamamoto, Dai Mohri, Yoshihiro Isomura, Motoko Seto, Hayato Nakagawa, Yoshinari Asaoka, Motohisa Tada, Miki Ohta, Hideaki Ijichi, Yoshihiro Hirata, Motoyuki Otsuka, Tsuneo Ikenoue, Shin Maeda, Shuichiro Shiina, Haruhiko Yoshida, Osamu Nakajima, Fumihiko Kanai, Masao Omata, Kazuhiko Koike.   

Abstract

BACKGROUND & AIMS: Some clinical findings have suggested that systemic metabolic disorders accelerate in vivo tumor progression. Deregulation of the phosphatidylinositol 3-kinase (PI3K)/Akt pathway is implicated in both metabolic dysfunction and carcinogenesis in humans; however, it remains unknown whether the altered metabolic status caused by abnormal activation of the pathway is linked to the protumorigenic effect.
METHODS: We established hepatocyte-specific Pik3ca transgenic (Tg) mice harboring N1068fs*4 mutation.
RESULTS: The Tg mice exhibited hepatic steatosis and tumor development. PPARγ-dependent lipogenesis was accelerated in the Tg liver, and the abnormal profile of accumulated fatty acid (FA) composition was observed in the tumors of Tg livers. In addition, the Akt/mTOR pathway was highly activated in the tumors, and in turn, the expression of tumor suppressor genes including Pten, Xpo4, and Dlc1 decreased. Interestingly, we found that the suppression of those genes and the enhanced in vitro colony formation were induced in the immortalized hepatocytes by the treatment with oleic acid (OA), which is one of the FAs that accumulated in tumors.
CONCLUSIONS: Our data suggest that the unusual FA accumulation has a possible role in promoting in vivo hepato-tumorigenesis under constitutive activation of the PI3K pathway. The Pik3ca Tg mice might help to elucidate molecular mechanisms by which metabolic dysfunction contributes to in vivo tumor progression.
Copyright © 2011 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21703185     DOI: 10.1016/j.jhep.2011.03.025

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  24 in total

1.  CPT2 downregulation adapts HCC to lipid-rich environment and promotes carcinogenesis via acylcarnitine accumulation in obesity.

Authors:  Naoto Fujiwara; Hayato Nakagawa; Kenichiro Enooku; Yotaro Kudo; Yuki Hayata; Takuma Nakatsuka; Yasuo Tanaka; Ryosuke Tateishi; Yohko Hikiba; Kento Misumi; Mariko Tanaka; Akimasa Hayashi; Junji Shibahara; Masashi Fukayama; Junichi Arita; Kiyoshi Hasegawa; Hadassa Hirschfield; Yujin Hoshida; Yoshihiro Hirata; Motoyuki Otsuka; Keisuke Tateishi; Kazuhiko Koike
Journal:  Gut       Date:  2018-02-06       Impact factor: 23.059

2.  Impact of histone demethylase KDM3A-dependent AP-1 transactivity on hepatotumorigenesis induced by PI3K activation.

Authors:  T Nakatsuka; K Tateishi; Y Kudo; K Yamamoto; H Nakagawa; H Fujiwara; R Takahashi; K Miyabayashi; Y Asaoka; Y Tanaka; H Ijichi; Y Hirata; M Otsuka; M Kato; J Sakai; M Tachibana; H Aburatani; Y Shinkai; K Koike
Journal:  Oncogene       Date:  2017-07-10       Impact factor: 9.867

Review 3.  Stearoyl-CoA desaturase 1 as a therapeutic target for cancer: a focus on hepatocellular carcinoma.

Authors:  Mortaza Raeisi; Leila Hassanbeigi; Fatemeh Khalili; Hengameh Kharrati-Shishavan; Mehdi Yousefi; Amir Mehdizadeh
Journal:  Mol Biol Rep       Date:  2022-07-29       Impact factor: 2.742

Review 4.  Recent advances in mouse models of obesity- and nonalcoholic steatohepatitis-associated hepatocarcinogenesis.

Authors:  Hayato Nakagawa
Journal:  World J Hepatol       Date:  2015-08-18

Review 5.  NAFLD, NASH and liver cancer.

Authors:  Gregory A Michelotti; Mariana V Machado; Anna Mae Diehl
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2013-10-01       Impact factor: 46.802

6.  Protection from non-alcoholic steatohepatitis and liver tumourigenesis in high fat-fed insulin receptor substrate-1-knockout mice despite insulin resistance.

Authors:  A Nakamura; K Tajima; K Zolzaya; K Sato; R Inoue; M Yoneda; K Fujita; Y Nozaki; K C Kubota; H Haga; N Kubota; Y Nagashima; A Nakajima; S Maeda; T Kadowaki; Y Terauchi
Journal:  Diabetologia       Date:  2012-09-07       Impact factor: 10.122

Review 7.  How Useful Are Monogenic Rodent Models for the Study of Human Non-Alcoholic Fatty Liver Disease?

Authors:  Jake P Mann; Robert K Semple; Matthew J Armstrong
Journal:  Front Endocrinol (Lausanne)       Date:  2016-11-16       Impact factor: 5.555

Review 8.  PI3K/SHIP2/PTEN pathway in cell polarity and hepatitis C virus pathogenesis.

Authors:  Aline Awad; Ama Gassama-Diagne
Journal:  World J Hepatol       Date:  2017-01-08

Review 9.  Modeling progressive non-alcoholic fatty liver disease in the laboratory mouse.

Authors:  Jesse D Riordan; Joseph H Nadeau
Journal:  Mamm Genome       Date:  2014-05-07       Impact factor: 2.957

Review 10.  Astrocyte elevated gene-1 (AEG-1): A key driver of hepatocellular carcinoma (HCC).

Authors:  Indranil Banerjee; Paul B Fisher; Devanand Sarkar
Journal:  Adv Cancer Res       Date:  2021-06-16       Impact factor: 6.242

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.